Copyright © 2006, European Society of Cardiology
Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor 
Department of Cardiovascular Medicine, Kyushu University Graduate School of Medical Sciences, 3-1-1 Maidashi, Higashi-ku, 812-8582 Fukuoka, Japan
* Corresponding author. Tel.: +81 92 642 5361; fax: +81 92 642 5374. Email address: ichiki{at}cardiol.med.kyushu-u.ac.jp
Objective: Telmisartan, an angiotensin II type 1 receptor (AT1R) antagonist, was found to have a unique property: it is a partial agonist of peroxisome proliferator-activated receptor gamma (PPAR
). Since previous studies have demonstrated that PPAR activators suppressed AT1R expression, we examined whether telmisartan affects AT1R expression in vascular smooth muscle cells.
Methods: Vascular smooth muscle cells were derived from the thoracic aorta of Wistar–Kyoto rat. Northern and Western blotting analysis were used to examine AT1R mRNA and protein expression, respectively. The DEAE-dextran method was used for transfection, and the promoter activity of AT1R was examined by luciferase assay.
Results: Telmisartan decreased the expression of AT1R at the mRNA and protein levels in a dose- and time-dependent manner. Decreased AT1R promoter activity with unchanged mRNA stability suggested that telmisartan suppressed AT1R gene expression at the transcriptional level. However, the expression of AT1R was not suppressed by other AT1R antagonists such as candesartan or olmesartan. Since the suppression of AT1R expression was prevented by pretreatment with GW9662, a PPAR antagonist, PPAR should have participated in the process. The deletion and mutation analysis of the AT1R gene promoter indicated that a GC box located in the proximal promoter region is responsible for the telmisartan-induced downregulation.
Conclusion: Our data provides a novel insight into an effect of telmisartan: telmisartan inhibits AT1R gene expression through PPAR activation. The dual inhibition of angiotensin II function by telmisartan – AT1R blockade and downregulation – would contribute to more complete inhibition of the renin–angiotensin system.
KEYWORDS Antihypertensive; Diuretic drugs; Atherosclerosis; Gene expression; Receptors; Renin–angiotensin system
Time for primary review 26 days
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Xiao, J. C. K. Leung, L. Y. Y. Chan, H. Guo, and K. N. Lai Protective effect of peroxisome proliferator-activated receptor-gamma agonists on activated renal proximal tubular epithelial cells in IgA nephropathy Nephrol. Dial. Transplant., July 1, 2009; 24(7): 2067 - 2077. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Miyazaki, T. Ichiki, T. Hashimoto, K. Inanaga, I. Imayama, J. Sadoshima, and K. Sunagawa SIRT1, a Longevity Gene, Downregulates Angiotensin II Type 1 Receptor Expression in Vascular Smooth Muscle Cells Arterioscler Thromb Vasc Biol, July 1, 2008; 28(7): 1263 - 1269. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Imayama, T. Ichiki, D. Patton, K. Inanaga, R. Miyazaki, H. Ohtsubo, Q. Tian, K. Yano, and K. Sunagawa Liver X Receptor Activator Downregulates Angiotensin II Type 1 Receptor Expression Through Dephosphorylation of Sp1 Hypertension, June 1, 2008; 51(6): 1631 - 1636. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Scalera, J. Martens-Lobenhoffer, A. Bukowska, U. Lendeckel, M. Tager, and S. M. Bode-Boger Effect of Telmisartan on Nitric Oxide-Asymmetrical Dimethylarginine System: Role of Angiotensin II Type 1 Receptor and Peroxisome Proliferator Activated Receptor {gamma} Signaling During Endothelial Aging Hypertension, March 1, 2008; 51(3): 696 - 703. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Roberge, A. C. Carpentier, M.-F. Langlois, J.-P. Baillargeon, J.-L. Ardilouze, P. Maheux, and N. Gallo-Payet Adrenocortical dysregulation as a major player in insulin resistance and onset of obesity Am J Physiol Endocrinol Metab, December 1, 2007; 293(6): E1465 - E1478. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Pravenec and T. W. Kurtz Molecular Genetics of Experimental Hypertension and the Metabolic Syndrome: From Gene Pathways to New Therapies Hypertension, May 1, 2007; 49(5): 941 - 952. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Martinson, M. P. Hans, G.-D. David, and A. M. Elizabeth Readers' choice: Hot papers downloaded in 2006 Cardiovasc Res, March 1, 2007; 73(4): 619 - 622. [Full Text] [PDF]
|
|